We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 03, 2022

Neoadjuvant Chemoradiotherapy vs Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
J. Clin. Oncol 2022 Jan 27;[EPub Ahead of Print], E Versteijne, JL van Dam, M Suker, QP Janssen, K Groothuis, JM Akkermans-Vogelaar, MG Besselink, BA Bonsing, J Buijsen, OR Busch, GM Creemers, RM van Dam, FALM Eskens, S Festen, JWB de Groot, B Groot Koerkamp, IH de Hingh, MYV Homs, JE van Hooft, ED Kerver, SAC Luelmo, KJ Neelis, J Nuyttens, GMRM Paardekooper, GA Patijn, MJC van der Sangen, J de Vos-Geelen, JW Wilmink, AH Zwinderman, CJ Punt, G van Tienhoven, CHJ van Eijck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading